Clinical Trial: Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment

U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07422610) titled 'Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment' on Jan. 22.

Brief Summary: The primary purpose of this study is to evaluate the impact of hepatic function on the pharmacokinetic (PK) profile of pelabresib in participants with advanced malignancies who have either hepatic impairment (HI) or normal liver function. To reduce participant burden and maximize benefit, the PK of pelabresib will be assessed at steady-state rather than after a single dose, avoiding treatment-free washout periods.

Study Start Date: May 18, 2026

Study Type: INTERVENTIONAL

Condition: Advanced Ma...